Home › Companies › EYPT

EyePoint

Market cap $34.1M 113.8M shares (10-Q, Nov 6, 2026) × $0.300 close Nov 17, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Workforce reduction corporate update1H 2027Workforce reduction corporate update, 1H 2027, routine
  2. EYPT corporate updatelate 3Q 2027EYPT corporate update, late 3Q 2027, routine
  3. COMO/CAPRI DME topline4Q 2027COMO/CAPRI DME topline, 4Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Technology platforms

Durasert E

Next-generation bioerodible intravitreal drug delivery technology designed to provide sustained release of drug for at least six months without free-floating drug particles; used as the delivery vehicle for vorolanib in DURAVYU for serious retinal diseases including wet AMD and DME.

Discontinued (1)

Capital (as filed)

Cash
$83.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$35.0M Sep 30, 2026
Operating cash flow
−$86.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$118M cash, runway late third quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on EyePoint, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products Asymmetric binary setup ahead of mid-2026 Phase 3 LUGANO/LUCIA readouts, backed by clean Phase 2 data, multi-MOA science, and cash runway that bridges the pre-data dilution gap.
  2. Buy core UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window Interim masked Phase 3 safety read across 900+ patients is clean and catalyst calendar is intact, though cash burn is faster than originally modeled and manufacturing risk remains unaddressed.
  3. Buy core UPDATE: EyePoint (EYPT) — The DOJ Overhang Clears for Pocket Change DOJ/False Claims Act settlement resolved for ~$4.85M (a rounding error vs. cash), narrowing the bear case to just the unresolved Watertown Warning Letter ahead of imminent LUGANO topline.
  4. Buy core UPDATE: EyePoint (EYPT) - The Binary Event Now Has a Month LUGANO topline tightened to August 2026, DSMC continuation across 1,400+ Phase 3 patients removes the most common failure mode, and DME enrollment completed ahead of schedule; Watertown remains the sole unaddressed risk.
  5. Buy core UPDATE: EyePoint (EYPT) - The Last Quarter Before the Verdict Clinical thesis and August LUGANO timing unchanged, but balance sheet is thinner than originally modeled after $37.7M ATM raise and $94.5M Q2 burn, with LUCIA now pushed to Q4 2026 amplifying single-trial readout variance.
  6. Hold UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis. LUGANO missed its primary endpoint on the full dataset; asset is damaged but not dead given clean anatomic data and burden reduction, with LUCIA now the sole binary event and a financing overhang as the near-term killer.
  7. Hold UPDATE: EyePoint (EYPT) - They Ran the Analysis I Asked For Expanded LUGANO analyses (no 10-14 letter imbalance, GA growth matching fellow eye, baseline lesion location imbalance) strengthen the asymmetric-cohort explanation but do not change what LUCIA must do; financing overhang and Watertown remain unresolved.
  8. Avoid UPDATE: EyePoint (EYPT) - Zero for Two LUCIA missed non-inferiority outright with a normal control arm, wet AMD program is being shut down, the failure was efficacy not bad luck, and the remaining DME program rests on a thin Phase 2 base with a cash position unlikely to reach the Q4 2027 readout unaided.
  9. Avoid UPDATE: EyePoint (EYPT) - The Runway Now Ends Before the Readout Management's own cash runway now ends before the Q4 2027 DME readout, a going-concern warning has been issued, 25% dilution occurred at $0.44/share, and the only remaining catalyst is a below-even-odds binary with no non-dilutive financing yet disclosed.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 19, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

16 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)